Investigating how hHv1 channels in neutrophils affect lung inflammation and injury
hHv1 channels in neutrophils and the innate immune inflammatory response
This study is looking at how a specific channel in white blood cells affects lung damage during serious conditions like acute lung injury and ARDS, and it aims to see if blocking this channel can help reduce inflammation and improve breathing for people with these issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10867338 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of hHv1 channels in neutrophils, which are a type of white blood cell involved in the body's immune response. The study aims to explore how these channels contribute to the release of reactive oxygen species (ROS) that can lead to lung damage, particularly in conditions like acute lung injury and acute respiratory distress syndrome (ARDS). By targeting the hHv1 channel with a specific blocker, the researchers hope to reduce inflammation and improve lung function. This approach is based on previous findings that suggest blocking hHv1 can suppress harmful immune responses in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults suffering from acute lung injury or acute respiratory distress syndrome.
Not a fit: Patients with chronic lung diseases or those not experiencing acute respiratory distress may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce lung damage and improve survival rates for patients with acute respiratory distress syndrome.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways for reducing inflammation, suggesting potential for success in this novel approach.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Goldstein, Steve a N — University of California-Irvine
- Study coordinator: Goldstein, Steve a N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.